Bench-to-bedside review: Antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit

Critical Care

Volumn 9, Issue 5, 2005, Pages 459-464

  Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CRITICAL ILLNESS; DRUG FORMULARY; FEBRILE NEUTROPENIA; HOSPITAL MANAGEMENT; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPSIS;

ANTI-INFECTIVE AGENTS; CRITICAL CARE; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FORMULARIES; HUMANS; INTENSIVE CARE UNITS; PRACTICE GUIDELINES; TIME FACTORS;

EID: 27144522642     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3757     Document Type: Review

References (86)

1. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996, 275:234-240.
2. Carlet J, Ben Ali A, Chalfine A: Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004, 17:309-316.
3. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study; EPIC International Advisory Committee. JAMA 1995, 274:639-644.
4. Waldvogel FA: New resistance in Staphylococcus aureus. N Engl J Med 1999, 340:556-557.
5. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ: Antibiotic susceptibility among aerobic Gram-negative Bacilli in intensive care units in 5 European countries. JAMA 1999, 281:67-71.
6. Quinn JP: Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998, 27: S117-S124.
7. Jones RN, Sader HS, Beach ML: Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003, 22:551-556.
8. Livermore DM: Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003, 36:S11-S23.
9. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873.
10. Shlaes DM, Gerding DN, John Jr JF, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, et al.: Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997, 25:584-599.
11. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP: Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003, 289:885-888.
12. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997, 24:211-215.
13. Sieradzki K, Roberts RB, Haber SW, Tomasz A: The development of Vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999, 340:517-523.
14. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, et al.: Emergence of Vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999, 340:493-501.
15. Van Looveren M, Goossens H: Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004, 10:684-704.
16. Canton R, Coque TM, Baquero F: Multi-resistant Gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 2003, 16:315-325.
17. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003, 11:154-160.
18. Livermore DM, Yuan M: Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp from intensive care units in Europe. J Antimicrob Chemother 1996, 38:409-424.
19. Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A: Association of Hospital Bacteriologists, Virologists and Hygiene Professionals. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004, 10:448-451.
20. Haley RW, Bregman DA: The role of understating and over-crowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit. J Infect Dis 1982, 145:875-885.
21. Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001, 134:298-314.
22. Kollef MH, Micek ST: Strategies to prevent antimicrobial resistance in the ICU. Crit Care Med 2005, in press.
23. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C: Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture technique. Am Rev Respir Dis 1989, 139:877-884.
24. Ortiz J, Vila MC, Soriano G, Minana J, Gana J, Mirelis B, Novella MT, Coll S, Sabat M, Andreu M, et al.: Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999, 29:1064-1069.
25. Kaplan SL, Mason EO Jr, Barson WJ, Wald ER, Arditi M, Tan TQ, Schutze GE, Bradley JS, Givner LB, Kim KS, et al.: Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 1998, 102:538-545.
26. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, Wenzel RP: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126-1133.
27. Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, Gordon SM: Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubed patients. Chest 1999, 115:1378-1382.
28. Rello J, Ausina V, Ricart M, Castella J, Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993, 104:1230-1235.
29. Kollef MH: Ventilator-associated pneumonia: a multivariate analysis. JAMA 1993, 270:1965-1970.
30. Kollef MH, Silver P, Murphy DM, Trovillion E: The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995, 108:1655-1662.
31. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, et al.: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 280:1233-1237.
32. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993, 119:353-358.
33. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, Rahal JJ: Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype antratus. J Infect Dis 1993, 167:448-451.
34. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157:531-539.
35. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, et al.: Comparison of 15 vs. 8 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
36. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001, 163:1371-1375.
37. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
38. Harbarth S, Ferriere K, Hugonnet S, Ricou B, Suter P, Pittet D: Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002, 137:1353-1359.
39. Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996, 22:387-394.
40. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115.
41. Kollef MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31:8131-8138.
42. Kollef MH, Sherman G, Ward S, Prentice D, Schaiff R, Huey W, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
43. Kollef MH, Ward S: The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113:412-420.
44. Rello J, Gallego M, Mariscal D, Sonora R, Valles J: The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:196-200.
45. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
46. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49:1306-1311.
47. Dhainaut JF, Laterre PF, LaRosa S, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, et al.: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003, 31:2291-2301.
48. Harbarth S, Garbino JK, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effects on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535.
49. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Gut Care Med 2003, 31:2742-2751.
50. Micek ST, Isakow W, Shannon W, Kollef MH: Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Pharmacotherapy 2005, 25:26-34.
51. Classen DC, Pestotnik SL1 Evans RS, Lloyd JF, Burke JP: Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997, 277:301-306.
52. Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP: Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994, 154:878-884.
53. Pestotnik SL, Classen DC, Evans RS, Burke JP: Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996, 124:884-890.
54. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, Lloyd JF, Burke JP: A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998, 338:232-238.
55. Bailey TC, Ritchie DJ, McMullin ST, Kahn M, Reichley RM, Casabar E, Shannon W, Dunagan WC: A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997, 17:277-281.
56. Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
57. McGowan Jr JE, Gerding DN: Does antibiotic restriction prevent resistance? New Horizons 1996, 4:370-376.
58. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM: Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998, 128:989-995.
59. Quale J, Landman D, Atwood E, Kreiswirth B, Willey BM, Ditore V, Zaman M, Patel K, Saurina G, Huang W, et al.: Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996, 24:372-379.
60. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R, Singer DE, Coley CM, Marrie TJ, Fine MJ: Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997, 278:32-39.
61. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R: Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999, 159:266-270.
62. McNulty C, Logan M, Donald IP, Ennis D, Taylor D, Baldwin RN, Bannerjee M, Cartwright KA: Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997, 40:707-711.
63. Wade, JC: Antibiotic therapy for the granulocytopenic cancer patient: combination therapy vs. monotherapy. Rev Infect Dis 1989, 11:81572-81581.
64. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L: Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004, 328:668.
65. Paul M, Soares-Weiser K, Leibovici L: Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003, 326:1111.
66. Chamot E, Boffi El Amari E, Rohner P, Van Delden C: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003, 47:2756-2764.
67. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
68. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA: Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000, 283:1583-1590.
69. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB: High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003, 37:752-760.
70. Niederman MS: Is 'crop rotation' of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 1997, 156:1029-1031.
71. Gruson D, Hilbert G, Vargas F, Valentino R, Bebear C, Allery A, Bebear C, Gbikpi-Benissan G, Cardinaud JP: Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000, 162:837-843
72. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V: Scheduled rotation of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 1997, 156:1040-1048.
73. Kollef MH, Ward S, Sherman G, Prentice D, Schaiff R, Huey W, Fraser V: Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000, 28:3456-3464.
74. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG: Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003, 31:1035-1041.
75. Hughes MG, Evans HL, Chong TW, Smith RL, Raymond DP, Pelletier SJ, Pruett TL, Sawyer RG: Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 2004, 32:53-60.
76. van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, Bonten MJ: Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 2005, 171:480-487.
77. Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, Fraser VJ, Fridkin SK: Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 2004, 32:2450-2456.
78. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996, 40:691-695.
79. Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia. Crit Care Med 2003, 31:2102-2106.
80. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, et al.: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467.
81. Lipman J, Wallis SC, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43:2559-2561.
82. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy, the importance of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
83. Blaser J, Stone BB, Groner MC, Zinner SH: Comparative study with enoxacin and netilmicin in a pharmcodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987, 31:1054-1060.
84. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME: Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989, 45:22-27.
85. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ: Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42:521-527.
86. Schentag JJ, Gilliland KK, Paladino JA: What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001, 32:S39-S46.